Highlights
Helminth therapy shows promise in modulating metabolic pathways and immune responses, offering potential benefits for type 2 diabetes (T2D) management. While early research suggests therapeutic value, translating these findings into clinical practice requires overcoming challenges related to safety and efficacy. Further large-scale clinical studies are necessary to confirm the potential of helminth-derived treatments for T2D.
Introduction
Over the past few decades, the incidence of diabetes mellitus (DM) has risen sharply, presenting a formidable public health challenge in the 21st century. According to the IDF Diabetes Atlas 10th edition, approximately 537 million adults aged 20 to 79 worldwide are afflicted by diabetes, predominantly T2D (IDF 2021) (Figure 1). By 2045, it is projected that the global diabetic population will reach 783 million. Notably, in regions with lower economic development, such as low-income countries, diabetes remains undiagnosed in 24% to 54% of cases (Harreiter and Roden Reference Harreiter and Roden2023; Priya et al. Reference Priya2020). Consequently, this escalating prevalence places substantial pressure on global healthcare systems. Despite initiatives by the WHO aimed at halting the increase in diabetes and obesity by 2025 (WHO 2023), effective treatments remain elusive. Many patients with advanced T2D require lifelong insulin therapy, underscoring the critical need for innovative therapeutic approaches.
Number of people with diabetes worldwide and per IDF Region in 2021–2045 (20–79 years).
Source: International Diabetes Federation. IDF Diabetes Atlas, 10th edn. Brussels, Belgium: 2021. Available at: https://www.diabetesatlas.org.

With advancements in global economics and health standards, diseases linked to unsanitary conditions like cholera and parasitic infections have been mitigated or eradicated in numerous countries. Conversely, the incidence of diseases associated with higher-income lifestyles, such as immune and metabolic disorders, including diabetes, continues to climb, as exemplified in the United States, China, and the United Kingdom (Bhopal and Rafnsson Reference Bhopal and Rafnsson2009; Einarson et al. Reference Einarson2018; Hernández et al. Reference Hernández2020; Ma et al. Reference Ma2022; Nowakowska et al. Reference Nowakowska2019). This trend aligns with the ‘hygiene hypothesis’ (Strachan Reference Strachan1989), which posits that excessive cleanliness may reduce microbial human contact, potentially leading to an overactive immune response to environmental triggers and contributing to autoimmune and allergic diseases (Rook Reference Rook2012). Indeed, rates of allergic diseases are typically lower among rural children compared to their urban counterparts (Ege et al. Reference Ege2011), supporting the notion that excessive environmental hygiene may contribute to the rising incidence of autoimmune diseases (Wills-Karp et al. Reference Wills-Karp, Santeliz and Karp2001).
Given the potential roles of parasites in metabolic and immune regulation, several species have been proposed as possible treatments for a range of conditions, including asthma (Fernandes et al. Reference Fernandes2019), inflammatory bowel disease (IBD) (Atagozli et al. Reference Atagozli, Elliott and Ince2023), celiac disease (Croese et al. Reference Croese2020), atherosclerosis (Yang et al. Reference Yang2022), non-alcoholic fatty liver disease (Liu et al. Reference Liu2022), and multiple sclerosis (MS) (Tanasescu et al. Reference Tanasescu2020). Similarly, helminthic therapy offers a promising and innovative treatment option for T2D (Gao et al. Reference Gao2021), driven by chronic inflammatory disorders, although its translation to clinical practice requires further exploration.
Type 2 diabetes and chronic inflammation
Compared to T1D, characterised by autoimmune-mediated destruction of pancreatic β-cells leading to an absolute deficiency in insulin secretion (Bluestone et al. Reference Bluestone, Buckner and Herold2021; Roep et al. Reference Roep2021), T2D involves insulin resistance (IR) and a relative insulin deficiency as a metabolic disorder (Hudish et al. Reference Hudish, Reusch and Sussel2019). Notably, T2D is also recognised as a chronic inflammatory condition often triggered by obesity (Figure 2). Since the 1960s, research has consistently demonstrated an increase in white blood cell (WBC) counts in patients with T2D, alongside elevated levels of systemic glycoproteins and acute phase reactants such as IL-1β, tumour necrosis factor TNF, and chemokines like CCL2, CCL3, and CXCL8 (Herder et al. Reference Herder2005; Spranger et al. Reference Spranger2003). These inflammatory markers may promote IR in primary tissues like the liver and fat and can also affect distant sites such as vascular walls, skeletal muscle, myocardium, and kidneys. The inflammation driven by circulating leukocytes exacerbates IR and perpetuates a harmful cycle.
The multifactorial pathogenesis of T2D. T2D is primarily a metabolic disorder characterized by IR and β-cell dysfunction. This condition is caused by genetic predispositions and environmental factors, which disrupt insulin signalling pathways. Diets rich in fats and sugars, coupled with insufficient physical activity, alterations in the gut microbiome, and pharmacological interactions, contribute to reduced insulin receptor sensitivity in adipose and muscle tissues. This resistance impairs the functionality and expression of insulin-dependent glucose transporters, such as glucose transporter type 4 (GLUT4), subsequently hindering glucose uptake and utilisation. Furthermore, in response to persistent IR, an increase in insulin production is compelled in pancreatic β-cells, a demand that may ultimately lead to β-cell exhaustion or apoptosis. Concurrently, chronic inflammation exacerbates this condition by modulating the cytokine network, including IL-6, TNF-α, and IL-1β, which disrupts insulin signalling and affects immune cell function, notably altering the balance between pro-inflammatory and anti-inflammatory T-cells.

The balance of Th1 and Th2 immune responses, regulated by CD4+ T-cell differentiation, is crucial for maintaining immune homeostasis (Kidd Reference Kidd2003). In T2D, this balance is disrupted, shifting towards an enhanced Th1 response and a diminished Th2 response (Madhumitha et al. Reference Madhumitha2014; Mahlangu et al. Reference Mahlangu2020). Lean adipose tissue typically exhibits an anti-inflammatory profile governed by regulatory T cells (Tregs), eosinophils (EOS), and macrophages (MΦ) activated by type 2 cytokines like IL-4, IL-5, and IL-13, indicative of a Th2 immune response (Hotamisligil Reference Hotamisligil2006). In contrast, obese adipose tissue under metabolic stress releases pro-inflammatory type 1 cytokines such as IFN-γ and TNF (Camaya et al. Reference Camaya, O’Brien and Donnelly2023), which trigger autoinflammatory responses, disrupting insulin signalling pathways and thus contributing to IR (Hirosumi et al. Reference Hirosumi2002). Therefore, the immune environment of adipose tissue directly affects insulin sensitivity and the risk of developing T2D (Michailidou et al. Reference Michailidou, Gomez-Salazar and Alexaki2022). Regulatory strategies targeting Th2 cytokines may help mitigate the progression of T2D (Lee and Lee Reference Lee and Lee2014; Odegaard and Chawla Reference Odegaard and Chawla2013), highlighting the potential of parasitic immunomodulation as a therapeutic strategy. However, it is essential to note that while Th2 responses are generally anti-inflammatory, they can, under certain conditions, induce pathological fibrosis, leading to organ failure (Kokubo et al. Reference Kokubo2022).
Basic medical research
Helminths affect host metabolism
Direct impact
Helminth infections significantly impact host energy metabolism by altering glucose absorption and metabolism. Initial research has demonstrated that these changes may occur through modifications in intestinal glucose transport receptors or alterations in acetylcholine (ACh)-induced contraction responses, mediated by IL-4 or IL-13 stimulated signal transducer and activator of transcription 6 (STAT6) signalling within the enteric nervous system (Madden et al. Reference Madden2002; Zhao et al. Reference Zhao2003). It has been shown in subsequent studies that helminths also modify intestinal M2 cells, decreasing sodium-glucose cotransporter 1 (SGLT1) expression while concurrently downregulating GLUT2 and upregulating GLUT1, thus shifting glucose absorption pathways (Notari et al. Reference Notari2014; Worthington et al. Reference Worthington2013). Recent findings have revealed the suppression of the transporter protein GLUT8 during Opisthorchis viverrini (O. viverrini) infections and alterations in glucose metabolism around host cells due to the total excretory-secretory (ES) antigens of Ascaris suum (A. suum) (Kha et al. Reference Kha2024; Koehler et al. Reference Koehler2021). In vivo, experiments by Koehler et al. (Reference Koehler2022) in mice have demonstrated significant transcriptional reductions in GLUT1, STAT6, hypoxia-inducible factor 1-alpha (HIF-1α), and peptide transporter 1 (PepT1) in the jejunum, and in GLUT2 and PepT1 expression in the ileum, indicating a detrimental effect on physiological transport mechanisms (Figure 3).
The interaction between intestinal worms and the microbiota. Helminths alter the host’s glucose absorption mechanisms by modifying the expression of specific glucose transporter isoforms in the intestinal epithelial cells. Concurrently, helminth infections stimulate a Th2-type immune response, leading to significant changes in the gut microbiota’s composition and functional dynamics. These immunological shifts are facilitated by an increase in the production of SCFAs by the microbiota, subsequently diminishing nutrient absorption by the host. Additionally, the altered microbiota impacts the enteric nervous system, affecting neurons, sensory nerves, and interneurons. This interaction extends to influence systemic neurotransmitter levels, including gamma-aminobutyric acid, serotonin, and dopamine, further illustrating the extensive biochemical interactions between helminths, the gut microbiota, and host physiology.

Adult Schistosoma mansoni (S. mansoni) worms reside in host veins, and their eggs accumulate in the liver, affecting both adipose and liver metabolism (Hussaarts et al. Reference Hussaarts2015). Cytokines such as IL-4 and IL-13 are critical for adipose tissue homeostasis (Su et al. Reference Su2018). In obese mice, the injection of S. mansoni antigens has been found to stimulate IL-33 release from adipocytes, activating ILC2s and promoting the infiltration of M2 cells and eosinophils into white adipose tissue, thereby enhancing metabolic functions (Hams et al. Reference Hams2016). Additionally, Ni et al. (Reference Ni2021) discovered that Schistosoma japonicum (S. japonicum) infections regulate lipid metabolism via microRNAs (miRNAs) pathways: the interaction of Sjp40 with CD36 on hepatocytes inhibits miR-802, enhancing the expression of Prkab1 or Prkaa1 and increasing phosphorylated AMP-activated protein kinase (AMPK) levels, leading to reduced hepatic lipid synthesis. Notably, Heligmosomoides polygyrus (H. polygyrus) infection in mice fed a high-fat diet has been shown to prevent obesity, dyslipidaemia, and glucose intolerance (Obi et al. Reference Obi2020). These studies illuminate the complex interactions between parasitic infections and host metabolic processes, offering innovative approaches for managing metabolic disorders.
Indirectly affects through the gut microbiome
Since the initial germ-free mouse experiments, the role of the gut microbiota in regulating energy metabolism has been extensively studied (Bäckhed et al. Reference Bäckhed2004). It has been established that microbial populations are crucial for energy extraction, lipid storage, and vitamin synthesis. Research has found that parasites depend on the host’s gut microbiota for nutrient acquisition and survival, suggesting that helminths may modulate the host’s metabolic state by altering the gut microbiome (Zhou et al. Reference Zhou2022).
Further investigations have explored the interactions between parasites and the host’s gut bacterial communities, particularly noting the diversity of Blastocystis sp. (Caudet et al. Reference Caudet2022), which is associated with an increased risk of T2D, IR, and metabolic syndrome (MetS). It has been shown that parasites secrete substances that inhibit specific bacterial populations while promoting the production of short-chain fatty acids (SCFAs) (Rausch et al. Reference Rausch2018), such as butyrate, propionate, and acetate, by the gut microbiome. Butyrate and propionate are particularly noted for enhancing insulin sensitivity in muscle and fat tissues, reducing blood glucose levels, and aiding obesity prevention and T2D risk reduction (Canfora et al. Reference Canfora, Jocken and Blaak2015; Gao et al. Reference Gao2009; Kimura et al. Reference Kimura2011; May and den Hartigh Reference May and den Hartigh2023). Significant reductions in weight gain under a high-fat diet in mother rats infected with H. polygyrus and their offspring have been attributed to changes in the gut microbiome and elevated SCFA levels (Su et al. Reference Su2023). SCFAs also play a positive role by strengthening the intestinal barrier, reducing inflammation and metabolic endotoxemia, thereby mitigating systemic inflammation and IR in diabetics (Peng et al. Reference Peng2009). Experimental evidence indicates that increases in SCFAs in helminth-infected mice strongly correlate with shifts in microbial populations. Studies have observed a rise in the Clostridiales order, known for its efficient SCFA production, across various infection models, highlighting the potential of SCFAs in modifying obesity and enhancing insulin sensitivity (Figure 3) (Canfora et al. Reference Canfora, Jocken and Blaak2015; Losol et al. Reference Losol2024; Ramanan et al. Reference Ramanan2016; Singh et al. Reference Singh2024; Sun et al. Reference Sun2024).
Additionally, infections with helminths such as H. Polygyrus, Nippostrongylus brasiliensis (N. brasiliensis), and Trichuris muris (T. muris), have been shown to increase the population of Lactobacillaceae, recognised for its probiotic potential through immune response regulation (Blander et al. Reference Blander2017; Fricke et al. Reference Fricke2015). Recent research has linked improvements in insulin sensitivity in diet-induced obesity (DIO) mice and Venezuelan hookworm infections to microbial community alterations, notably an increase in lactobacilli and decreased intestinal permeability. Further studies indicate that H. Polygyrus infection may offer protective effects against obesity by indirectly modulating norepinephrine (NE) concentrations through microbial community changes (Shimokawa et al. Reference Shimokawa2019), with Th2 cells significantly facilitating metabolic enhancements by influencing microbial shifts (Su et al. Reference Su2020).
Parasites regulate host immune responses
Many parasites must deploy evasion strategies against the mammalian immune system to ensure long-term survival within their definitive hosts. These parasites can cause chronic infections in host tissues and typically induce a shift in the host immune response toward an anti-inflammatory phenotype while suppressing pro-inflammatory responses (Figure 4) (Loke and Harris Reference Loke and Harris2023).
Parasitic infections induce complex interactions between intestinal epithelial layers and immune cells to regulate the host immune response finely. In the intestinal mucosa, host cells instigate the activation of specific immune cell subsets via antigen presentation and cytokine release. A, Notably, antigens are relayed to dendritic cells (DCs) through the recognition mechanisms of Peyer’s patches. B, The immune response modulation following an infection in the mesenteric lymph nodes encompasses interactions among T cell subsets, including the activation and equilibrium of Th1, Th2, Th17, and Treg cells. C, Within the intestinal muscular layer, immune cells such as eosinophils and MCs react to parasitic infections by secreting anti-inflammatory mediators like IL-4, which notably influences the shift of MΦ towards an M2 phenotype. D, Additionally, the eggs of helminths exhibit inherent capabilities for immune evasion. This overview outlines immune cells’ complex interplay and strategic responses to maintain intestinal integrity and combat parasitic threats.

Inflammation triggered by MΦ plays a crucial role in the dysfunction of pancreatic β-cells. Within the islets, MΦ regulates the survival and metabolic activity of β-cells by acting as sensors, engaging in bi-directional exchanges of signals such as cytokines, hormones, and growth factors (Cosentino and Regazzi Reference Cosentino and Regazzi2021). However, in the progression of T2D, inflammatory signals disrupt this physiological equilibrium, resulting in interactions between MΦ and β-cells that lead to β-cell dysfunction and apoptosis. Specifically, early-stage T2D is characterised by pancreatic hypoxia that induces cellular stress and necrosis, releasing fatty acids and intracellular substances that activate the transcription inhibitor basic helix-loop-helix family member e40 (BHLHE40) (Tsuyama et al. Reference Tsuyama2023), impairing insulin secretion. These conditions foster the transformation of MΦ into a pro-inflammatory state (M1 type), with increased levels of IL-12 and decreased IL-10 exacerbating the inflammation (Ward et al. Reference Ward, Li and Hao2018; Yang et al. Reference Yang, Zhao and Jia2023). Furthermore, the upregulation of miR-212-5p in M1 macrophage-derived exosomes (M1-Exos) and high-fat diet-derived exosomes (HFD-Exos) influences β-cell insulin secretion by modulating the sirtuin two gene and the Akt/glycogen synthase kinase-3 beta/β-catenin (Akt/GSK-3β/β-catenin) pathway (Qian et al. Reference Qian2021), also generating pro-inflammatory mediators such as NO and reactive ROS, and expressing chemokine receptors like C-C motif chemokine receptor type 5 (CCR5), C-X-C motif chemokine receptor type 3 (CXCR3), and CCR8, which recruit pro-inflammatory cells (Dludla et al. Reference Dludla2023). Parasitic infections often induce a Th2 immune response in the host, promoting intestinal ‘clearance and excretion’ processes like increased mucus production and intestinal contractions, thus altering the gut microbiota (Dickson Reference Dickson2016; Ramanan et al. Reference Ramanan2016). These microbiota alterations enhance host metabolic functions by increasing levels of anti-inflammatory cytokines, transitioning adipose tissue MΦ from an M1 to an M2 phenotype, boosting the expression of tight junction proteins in intestinal cells, and lowering serum lipopolysaccharides (LPS) (Pace et al. Reference Pace2018). Mishra et al. (Reference Mishra2014) observed that in obese mice infected with S. mansoni, MΦ differentiation in white adipose tissue shifted towards an anti-inflammatory M2 phenotype, benefiting reductions in body weight and fat mass (FM) and enhancing glucose tolerance and insulin sensitivity. This was further supported by a study by Kang et al. (Reference Kang2021), where mice on a high-fat diet (HFD) infected with whipworms showed significantly lower increases in body weight, fat content, total cholesterol, and food efficiency ratio levels compared to uninfected controls. This protective effect is closely associated with the parasite’s ability to synergistically induce M2 through anti-inflammatory mediators such as IL-4 (Jensen et al. Reference Jensen2020), promoting their proliferation and inhibiting inflammatory responses.
Numerous studies have confirmed that several worms can modulate human Th1/Th2 cells and cytokines, steering inflammatory responses towards a Th2-dominated immune reaction and ameliorating conditions like obesity or malnutrition (Schmidt et al. Reference Schmidt2022). Research involving subjects infected with worms has shown varying improvements in metabolic health. Typically, worm infections increase Th2 cytokines, such as IL-4 and IL-13, while decreasing Th1 cytokines like IL-12 and IFN-γ (Vacca and Le Gros Reference Vacca and Le Gros2022). These cytokines further orchestrate the immune response, facilitating the recruitment of eosinophils, the production of B-cell-like entities, and the activation of alternative MΦ (Allen and Maizels Reference Allen and Maizels2011; Maizels and McSorley Reference Maizels and McSorley2016). The equilibrium between Th17 cells and Treg cells, both critical T cell subsets, is essential for maintaining immune homeostasis. Clinical data reveal that diabetic patients exhibit significantly elevated levels of Th17 and Th1 cells and reduced Treg cells (P < 0.01) (Li et al. Reference Li2022). Furthermore, Treg levels inversely correlate with high glucose levels, and diabetic patients experience more significant fluctuations in average glucose levels compared to those with normal albuminuria (P < 0.05) (Gu et al. Reference Gu2023). It is hypothesised that elevated blood glucose may increase Th1 and Th17 cells and inflammatory cytokines, impeding improvements in T2D (Varghese and Jialal Reference Varghese and Jialal2023). Experimental evidence suggests that infection with the H. polygyrus parasite increases the expression of IL-10 and adiponectin, reduces levels of leptin and anti-insulin, and enhances the infiltration of Th2 cells and eosinophils in adipose tissue – particularly enhancing the functionality and expression of activation markers, such as latency-associated peptide and CD134 in Treg cells (Queiroz-Glauss et al. Reference Queiroz-Glauss2022).
The proliferation of eosinophils is a distinguishing feature of host immune responses, enabling the differentiation of parasitic infections from other pathogenic challenges. In T2D development, eosinophils are pivotal in mediating Th2-type immune responses. IL-10, secreted by eosinophils, orchestrates these responses and limits local NO production. Parasites dependent on chronic infections may leverage this adaptive mechanism to sustain their presence and manipulate host immune responses (Fabre et al. Reference Fabre2009; Huang et al. Reference Huang2014). Research indicates that eosinophils are the primary cells expressing IL-4 in the adipose tissue of mice. When subjected to an HFD, mice lacking eosinophils exhibit increased adiposity, diminished glucose tolerance, and heightened IR. Therefore, eosinophils are essential for maintaining glucose equilibrium and countering metabolic disturbances induced by HFD (Wu et al. Reference Wu2011). In experimental models of diet-induced T2D in mice, administering the parasitic nematode N. brasiliensis for prevention and treatment significantly ameliorated fasting glucose levels, oral glucose tolerance, and weight gain, a process linked to increased EOS counts in mesenteric lymph nodes, liver, and adipose tissue (Kludhair et al. Reference Khudhair2020).
Additionally, mast cells (MCs) have been shown to influence immune regulation significantly. During infections with Hymenolepis diminuta (H. diminuta), activated MCs are instrumental in modulating the production of Th2 cytokines, contributing to a robust Th2-skewed immune response and expedited recovery in mice (da Silva et al. Reference da Silva, Jamur and Oliver2014; McKay Reference McKay2010).
Clinical medical research
The relationship between the prevalence of parasitic diseases and the prevalence of T2D
Scientists initially observed that parasitic infections in rural areas appeared to confer a protective effect against metabolic disorders such as diabetes and atherosclerosis (Chen et al. Reference Chen2013; Shen et al. Reference Shen2015). Notably, the incidence of MetS was significantly lower in populations previously infected with schistosomiasis (18.28%) compared to those uninfected (34.01%) (Shen et al. Reference Shen2015).
Recent research has increasingly focused on exploring the potential connections between parasitic infections and T2D (Molan et al. Reference Molan2020). Surveys across various global regions consistently indicate a negative correlation between the prevalence of parasitic infections and T2D rates. For instance, a study highlighted that the T2D incidence among those previously infected with schistosomiasis (14.9% infection rate) was markedly lower than in non-infected individuals (25.4% incidence rate) (Chen et al. Reference Chen2013). An Australian study also found that past infection with faecal nematodes (ELISA titre ≥0.3) was associated with a 61% reduced likelihood of T2D diagnosis compared to uninfected individuals (P = 0.001) (Hays et al. Reference Hays2015). Furthermore, there was a negative correlation between faecal nematode infection and T2D97 in Northeast Thailand. Research from Cameroon also emphasised the potential protective role of Loa infection against IR and metabolic diseases (Lenz et al. Reference Lenz2023) (Figure 5).
Advances in research on helminthic therapy. Initial epidemiological studies identified a negative correlation between helminth infection rates and T2D. The OR indicated in the data figure from the study by Chen et al. (Reference Chen2013) (doi:10.1210/jc.2012-2517) illustrates the strength and direction of this association, offering empirical support for hypotheses evaluating the effects of schistosomiasis infections on such metabolic conditions. Subsequent studies utilise methods like blood monitoring and deworming treatments to inversely investigate the influence of parasites on the clinical markers of T2D. Progressively, more precise controlled trials are being initiated.

Nonetheless, the association between parasitic infections and T2D is not consistently supported across studies. For example, Salvador’s case-control study did not establish any link between helminth infections and diabetes or other metabolic diseases (Salvador et al. Reference Salvador2023). Moreover, some studies indicate that certain parasitic infections might increase the risk of T2D (Bafghi et al. Reference Bafghi, Afkhami-Ardekani and Tafti2015). A cross-sectional study in the Lao People’s Democratic Republic revealed a positive correlation between tapeworm infections and both increased Glycated haemoglobin (HbA1c) levels and diabetes risk (Htun et al. Reference Htun2018), illustrating the complex and varied nature of the relationship between parasitic infections and T2D.
Metabolism-related evidence
Early research indicates that obese patients at risk for T2D may be infected with unicellular intestinal parasites, which, surprisingly, do not elicit notable clinical symptoms. Instead, these parasites appear to bolster the antioxidant defences in such patients (Caudet et al. Reference Caudet2022). Concurrently, studies by Wiria et al. (Reference Wiria2015) have demonstrated that various soil-transmitted helminths, including Ascaris and duodenal hookworms, improve body mass index (BMI) and enhance tissue insulin sensitivity.
Further investigations revealed that the prevalence of metabolic syndrome – including central adiposity, hypertension, hyperglycaemia, hypertriglyceridemia, and low high-density lipoprotein (HDL) cholesterol levels – was significantly lower in the experimental group with schistosomiasis compared to the control group (32.7% vs. 42.3%) (Mohamed et al. Reference Mohamed2017). Subsequent trials provided evidence that these benefits likely arise from parasitic colonisation in the host (Duan et al. Reference Duan2018), which reduces abdominal fat accumulation (Caudet et al. Reference Caudet2022). Additionally, S. haematobium significantly decreases the circulating levels of cholesterol-associated lipoprotein particles, underscoring the parasites’ potential influence on metabolic disorders (Zinsou et al. Reference Zinsou2020). Notably, a meta-analysis has indicated that certain parasitic infections confer metabolic benefits, such as lowering fasting glucose and HbA1c levels and reducing the incidence of MetS and T2D, particularly with S. mansoni infections (Rennie et al. Reference Rennie2021). Earlier, Aravindhan et al. (Reference Aravindhan2010a, Reference Aravindhan2010b) had shown that lymphatic filariasis (LF) infection modulates the cytokine profile of serum in T2D patients, with their study on LF’s impact on endocrine dysfunction in MetS and non-MetS patients over a 10-year period revealing notable IR in MetS patients, which was not moderated by LF infection; compared to the LF MetS group, subjects in the LF MetS group exhibited higher glucagon levels. LF infection also increased glucose-dependent insulinotropic polypeptide (GIP) and adipsin in MetS subjects (Sibi et al. Reference Sibi2022). Another cross-sectional study demonstrated that O. viverrine infection could lower HbA1c levels while raising HDL levels, effectively combating hyperglycaemia (OR 0.482, p = 0.040) and reducing the risk of metabolic diseases (OR 0.478, p = 0.030). In OV-positive individuals, HbA1c levels were lower (5.5% vs. 6.01%, p = 0.001), and HDL levels were higher (54.07 vs. 49.46 mg/dL, p = 0.001), with these differences being statistically significant (Muthukumar et al. Reference Muthukumar2020). Deworming treatments further validate the therapeutic effects of helminths, as demonstrated when praziquantel (PZQ) treatment administered to OV-positive subjects significantly increased HbA1c and HDL levels during the follow-up (Muthukumar et al. Reference Muthukumar2020). Similarly, a study in Iraq’s Kirkuk region found that T2D patients infected with various intestinal parasites, including Blastocystis hominis, exhibited increased WBC and lymphocyte counts but decreased haemoglobin levels among the 106 participants, 67 of whom were parasite-infected T2D patients and 39 were controls (Ahmed et al. Reference Ahmed, Ali and Mardan2023) (Figure 5).
Immunology-related evidence
Patients exhibiting low blood glucose levels and complex T2D typically experience marked elevations in total WBCs, neutrophils, monocytes, neutrophil to lymphocyte ratio (NLR), monocyte to lymphocyte ratio (MLR), mean platelet volume to lymphocyte ratio (MPVLR), and platelet to lymphocyte ratio (PLR). Conversely, parameters related to red blood cells and their indices notably decrease (Regassa et al. Reference Regassa2023). These findings suggest a potential immunological linkage between parasitic infections and the pathophysiology of T2D.
Given the ethical and practical limitations on directly studying human or animal infections by parasites, the correlation between parasitic infections and T2D remains to be fully established. Researchers have, therefore, utilised an indirect approach, employing anthelmintic treatment as a control to assess the impact of parasitic infections on diabetes-associated biomarkers by examining changes in these markers before and after treatment. This method serves to indirectly confirm the role of parasitic infections in altering diabetes-related indicators. The placebo-controlled trial by Tahapary et al. (Reference Tahapary2015) provided a novel opportunity to investigate the causal relationships between human helminth infections, systemic inflammation, and glucose metabolism. Results indicated that albendazole substantially lowered the prevalence of soil-transmitted helminths (STH), total IgE, and EOS counts. While no significant impact on IR was observed at the community level (treatment effect: 0.006, P = 0.48), albendazole significantly exacerbated IR in individuals with helminth infections (treatment effect: 0.031, P = 0.04) (Tahapary et al. Reference Tahapary2017a). The study also noted a significant decrease in adiponectin levels (0.91, P = 0.020) and an upward trend in leptin levels (1.10, P = 0.119) (Tahapary et al. Reference Tahapary2017b). Although there is no direct link between Strongyloides stercoralis (S. stercoralis) infections and T2D, Rajamanickam proposed that such infections could provide a protective effect against T2D by moderating the inflammatory environment typical of the disease. Supporting this, a study comparing inflammatory cytokines and chemokines in patients with T2D with and without S. stercoralis infection before and after antiparasitic treatment found that infected patients exhibited elevated Th2 and regulatory cell levels and reduced Th1 and Th17 cytokine levels, which normalised post-treatment (Rajamanickam et al. Reference Rajamanickam2020). This pattern suggests that S. stercoralis infections may beneficially modulate critical diabetic biochemical markers. Further analysis revealed that deworming led to significant reductions in pro-inflammatory cytokines-IL-1α, IL-1β, IL-6, IL-12, IL-18, IL-23, IL-27, G-CSF, and GM-CSF and chemokines-CCL1, CCL2, CCL3, CCL11, CXCL1, CXCL2, CXCL8, CXCL9, CXCL10, and CXCL11. In infected individuals, levels of the anti-inflammatory cytokineIL-1Ra were notably elevated (Rajamanickam Reference Rajamanickam2020).
Can worms be administered to treat diseases? To date, there is insufficient evidence to confirm whether controlled worm infections are safe for humans, whether they can enhance metabolic health, or potentially prevent the progression to T2D. Previous research by Pierce et al. (Reference Pierce2019) demonstrated that human volunteers could safely be infected with low-dose hookworms to treat various inflammatory diseases and MetS related to obesity (Croese et al. Reference Croese2015; Croese et al. Reference Croese2020; Tanasescu et al. Reference Tanasescu2020). While these studies did not examine outcomes related to metabolic health, substantial evidence suggests that hookworms can provoke type 2 and regulatory immune responses and alter the microbiome, potentially benefiting T2D patients (Croese et al. Reference Croese, Gaze and Loukas2013; Cantacessi et al. Reference Cantacessi2014). A pioneering study in Australia involved the deliberate infection of subjects with larvae to assess their impact on individuals at risk for developing T2D. Forty participants were randomly assigned into three groups to receive a placebo: 20 hookworm larvae or 40 hookworm larvae. The larvae were administered through the skin in two sessions, at the start and two months into the trial. Every six months for two years, the participants underwent evaluations, including physical exams, vital signs checks, adverse events reviews, and collections of biological samples and questionnaires. The primary outcomes focused on safety (evaluated through adverse events and completion rates) and changes in IR, which were assessed using the HOMA-IR. Secondary outcomes included analyses of fasting glucose levels, body weight, and adverse events. Results indicated an increase in adverse events among those treated with hookworms, with 44% experiencing expected gastrointestinal symptoms; however, the completion rates were similar to those of the placebo group. After one year, reductions were noted in fasting glucose levels and IR among those treated with hookworms, and after two years, a decrease in body weight was observed. This study suggests that hookworm infection is safe for individuals at risk for T2D and is associated with improvements in IR, justifying further investigation into the metabolic benefits of hookworms (Pierce et al. Reference Pierce2023). Additionally, the interaction between S. stercoralis infection and T2D has garnered scientific interest. A 2021 study by Rajamanickam et al. showed that following antiparasitic treatment, individuals infected with Ss exhibited significant increases in blood levels of angiogenic factors such as vascular endothelial growth factors A (VEGF-A), VEGF-C, and VEGF-D, and their receptors, vascular endothelial growth factor receptors 1 (VEGF-R1), VEGF-R2, and VEGF-R3 and ligands associated with advanced glycation end products (AGEs), such as soluble receptor for advanced glycation end products (sRAGE), S100 calcium-binding protein A12 (S100A12), and high mobility group box 1 (HMGB-1). This suggests that parasites may slow T2D progression by suppressing the expression of markers associated with vascular complications (Rajamanickam et al. Reference Rajamanickam2021). Further research in 2024 has explored the effects of S. stercoralis infection on the complement system, a crucial immune regulatory mechanism. It was found that T2D patients with Ss infection experienced partial restoration of complement proteins, such as C1q, C4b, and mannose-binding lectin, and complement regulatory factors like factor B and factor D after antiparasitic treatment. This indicates that Ss infection might mitigate inflammatory responses by reducing complement activation, thus offering potential protective benefits against T2D. Both studies endorse the potential of parasites as a novel therapeutic approach for T2D, providing valuable biological evidence for future treatment strategies (Figure 5) (Rajamanickam et al. Reference Rajamanickam2024).
Conclusion
Helminth therapy, as a potential treatment for T2D, represents a promising intersection between parasitology and metabolic disease research. The evidence presented in this review suggests that helminths can play diverse roles in modulating host metabolism and immune responses, offering novel therapeutic strategies for managing T2D. However, several challenges must be addressed before helminth therapy can be widely implemented in clinical practice. Chief among these concerns are the potential side effects and the uncertain long-term impacts of introducing parasites into the human body. Currently, parasitic organisms are considered unsafe, as infections can lead to additional health problems, including malnutrition (Nolan et al. Reference Nolan2021), anaemia (Apaza et al. Reference Apaza2023), and intestinal obstruction (Ali et al. Reference Ali, Mohamed Abdi and Mambet2023). Moreover, not all parasites are associated with diabetes; for example, Salvador et al. (Reference Salvador2023) found no link between larval toxocariasis and diabetes or other metabolic disorders. Therefore, careful consideration is required regarding the potential for adverse immune reactions, exacerbation of other chronic conditions, and the risks of parasite persistence or transmission. The study by Dabirzadehd et al. (Reference Dabirzadeh, Sargazi and Bagheri2024) highlighted risk factors that could increase the susceptibility of diabetic patients to Toxoplasma gondii infection, such as the immunocompromised state caused by diabetes. Additionally, different types of diabetes require distinct considerations. For instance, a meta-analysis found a positive association between Toxoplasma gondii infection and type 1 diabetes (Catchpole et al. Reference Catchpole2023). In patients with gestational diabetes mellitus, IgG affinity was significantly lower than in the control group, and levels of IFN-γ, IL-10, and IL-17 CD4+ T cells were significantly reduced, along with diminished Th1, Th2, and Th17 immune responses (Oliveira-Scussel et al. Reference Oliveira-Scussel2022). Helminth therapy is still in its early stages. In northeastern Thailand, S. stercoralis infection was found to be negatively associated with T2D. However, infected individuals displayed abnormal kidney and liver function markers, and the infection could lead to CMV co-infection in immunocompromised patients (Wang et al. Reference Wang, Guo and Liu2023), potentially worsening kidney-related complications (Yingklang et al. Reference Yingklang2022). The mite Demodex folliculorum, associated with altered immune responses, may also be linked toT2D (Bendezu-Quispe et al. Reference Bendezu-Quispe, Rojas-Zevallos and Rosales-Rimache2022; Gökçe et al. Reference Gökçe2013).
Furthermore, ethical and logistical challenges, such as patient acceptance and the creation of standardised treatment protocols, present additional hurdles. Future research should focus on optimising helminth therapy to mitigate these risks, potentially through advances in biotechnology. For instance, developing helminth-derived molecules or synthetic analogues that replicate the beneficial effects of live parasites (Khudhair et al. Reference Khudhair2020; Khudhair et al. Reference Khudhair2022) could offer a safer alternative. Additionally, a personalised medicine approach, where helminth therapy is tailored to individual patient characteristics, may improve efficacy while reducing adverse effects. Although helminth therapy holds significant promise for clinical application, it requires cautious and rigorous research. Overcoming these challenges and uncertainties will be crucial to harnessing the therapeutic potential of helminths in the treatment of T2D.
Acknowledgements
This research was funded by the National Natural Science Foundation of China (Grant No: 32000293); Guangxi Natural Science Foundation (Grant Nos: 2020JJA130077 and 2018JJB140423); the University Level Scientific Research Project of Zhejiang Shuren University (Grant No: 2022R064); Zhejiang Shuren University Basic Scientific Research Special Funds (Grant No: 2024XZ014); Zhejiang Shuren College Campus level Scientific Research Project(2023A11001).
Competing interests
The authors have no relevant financial or non-financial interests to disclose.
Ethical standard
This article is a review of previously published studies and does not contain any new studies with human participants or animals performed by the authors.
